靶向骨髓中的癌症相关成纤维细胞可预防多发性骨髓瘤对CART细胞治疗的耐药
该研究利用多发性骨髓瘤(MM)模型,探讨癌症相关成纤维细胞(CAFs)对B细胞成熟抗原靶向CART细胞疗效的影响,并开发克服抑制的策略。结果显示CAFs抑制CART细胞抗肿瘤活性并促进MM进展,而同时靶向MM细胞和CAFs的双靶点CART细胞策略显著改善效应功能,为克服MM中CART细胞治疗耐药提供了新策略。
要点
- CAFs抑制CART细胞抗肿瘤活性并促进多发性骨髓瘤进展。
- CAFs表达成纤维细胞活化蛋白和信号淋巴细胞激活分子家族-7等免疫治疗靶点。
- 双靶向MM细胞和CAFs的CART细胞策略显著改善效应功能。
核心结论
- 同时靶向恶性浆细胞和肿瘤微环境中的CAFs是克服MM中CART细胞治疗耐药的新策略。
研究设计与样本
- 使用多发性骨髓瘤模型研究CAFs对CART细胞疗效的影响并开发克服抑制的策略。
主要发现
- CAFs抑制CART细胞抗肿瘤活性并促进MM进展。
- CAFs表达成纤维细胞活化蛋白和信号淋巴细胞激活分子家族-7等免疫治疗靶点。
- 同时靶向MM细胞和CAFs的双靶点CART细胞显著改善CART细胞效应功能。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pivotal clinical trials of B-cell maturation antigen-targeted chimeric antigen receptor T (CART)-cell therapy in patients with relapsed/refractory multiple myeloma (MM) resulted in remarkable initial responses, which led to a recent US Food and Drug Administration approval. Despite the success of this therapy, durable remissions continue to be low, and the predominant mechanism of resistance is loss of CART cells and inhibition by the tumor microenvironment (TME). MM is characterized by an immunosuppressive TME with an abundance of cancer-associated fibroblasts (CAFs). Using MM models, we studied the impact of CAFs on CART-cell efficacy and developed strategies to overcome CART-cell inhibition. We showed that CAFs inhibit CART-cell antitumor activity and promote MM progression. CAFs express molecules such as fibroblast activation protein and signaling lymphocyte activation molecule family-7, which are attractive immunotherapy targets. To overcome CAF-induced CART-cell inhibition, CART cells were generated targeting both MM cells and CAFs. This dual-targeting CART-cell strategy significantly improved the effector functions of CART cells. We show for the first time that dual targeting of both malignant plasma cells and the CAFs within the TME is a novel strategy to overcome resistance to CART-cell therapy in MM.
引用
- Sakemura R, Hefazi M, Siegler EL, et al. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood. 2022. PMID: 35090171. doi:10.1182/blood.2021012811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。